M
Malladi Drugs
Pharmaceutical manufacturing company manufacturing medicines
About Malladi Drugs
Malladi Drugs & Pharmaceuticals Ltd. is an established manufacturer of Active Pharmaceutical Ingredients (APIs) based in India, with a significant global footprint. Founded in 1980 by the late Mr. M L N Sastry, a microbiologist with deep expertise in fermentation technology, the company pioneered the manufacturing of Ephedrine and Pseudoephedrine salts in India through a fully indigenous process. This early focus on bi-synthetic processes established the firm's knowledge-driven approach.
The company's core business involves the development and distribution of APIs, with a primary focus on the cough and cold therapeutic segment. Over the years, Malladi has expanded its portfolio to include other key areas such as anti-histamines, anti-convulsants, anti-depressants, and anxiolytics. Its business model is centered on supplying these APIs to large pharmaceutical companies globally, with exports to over 60 countries accounting for more than 85% of its revenue. A key strategic partnership exists with Bayer AG, for whom Malladi exclusively produces certain products. In addition to API sales, the company generates revenue through contract manufacturing, custom synthesis, and contract research services, supporting clients from clinical research to large-scale production.
Malladi operates three cGMP manufacturing facilities in India—two in Ranipet, Tamil Nadu, and one in Renigunta, Andhra Pradesh—which have been inspected and approved by numerous international regulatory agencies, including the US FDA, EDQM (Europe), and TGA (Australia). The company also operates a state-of-the-art R&D center near Chennai, which is a recognized center for doctoral programs. A significant milestone was the acquisition of Novus Fine Chemicals in New Jersey, USA, making it the first Indian company to acquire an API manufacturing facility outside of India. The company recently raised INR 2,500 million from the India Life Sciences Fund to facilitate capacity expansion and the launch of new molecules.
Source: Dealroom company dataNews
Open roles
Malladi Drugs in the Chennai ecosystem
The Malladi Drugs office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later1 investor entered at this stage
Invascent
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Malladi Drugs on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Malladi Drugs on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

